Prevalence and survival implications of malnutrition and sarcopenia in metastatic breast cancer: A longitudinal analysis.

Breast neoplasms Malnutrition Sarcopenia Survival

Journal

Clinical nutrition (Edinburgh, Scotland)
ISSN: 1532-1983
Titre abrégé: Clin Nutr
Pays: England
ID NLM: 8309603

Informations de publication

Date de publication:
14 Jun 2024
Historique:
received: 05 04 2024
revised: 28 05 2024
accepted: 08 06 2024
medline: 22 6 2024
pubmed: 22 6 2024
entrez: 22 6 2024
Statut: aheadofprint

Résumé

Malnutrition and sarcopenia are challenges for patients with metastatic breast cancer and have been proposed as independent prognostic factors. Very few studies have addressed the temporal evolution of these parameters and, notably, the separate and combined analysis of sarcopenia and malnutrition. This study aimed to i) determine the prevalence of malnutrition and sarcopenia, individually and combined, and their evolution over time, ii) identify risk factors for each condition, and iii) explore their impact on overall survival (OS). This retrospective study was conducted on 111 patients treated for at least a third-line metastatic breast cancer at the Institut Curie between January 1st and March 31st, 2018. Solitary malnutrition was defined from weight loss and body mass index values while solitary sarcopenia was defined solely based on low muscle mass. We analyzed solitary malnutrition, solitary sarcopenia, and then malnutrition with or without sarcopenia, at three key stages (T1: diagnosis of metastasis, T2: initiation of third-line treatment, and T3: 3-month re-evaluation). Univariate and multivariate logistic regression analyses were conducted to investigate the risk factors. We performed Cox proportional hazards analyses for each variable. At T1, the prevalence of solitary malnutrition, solitary sarcopenia and malnutrition with or without sarcopenia was 18.6%, 36.1% and 48.9% respectively, increasing to 27.7%, 45.5% and 56.6% at T2. At T2, in multivariate logistic regression analyses, patients aged over 60 years were at an elevated risk of experiencing solitary malnutrition as well as malnutrition with or without sarcopenia, but not solitary sarcopenia. In multivariate analyses, solitary malnutrition was significantly associated with poorer OS (HR 2.2 [95% CI 1.1-4.1], p = 0.02), while solitary sarcopenia and malnutrition with or without sarcopenia showed no association. Solitary malnutrition and sarcopenia were highly prevalent in patients with metastatic breast cancer, affecting around a quarter and half of patients respectively at third-line treatment initiation. Notably, solitary malnutrition emerged as a prognostic factor for overall survival, whereas no significant association was observed for solitary sarcopenia or malnutrition with or without sarcopenia. This highlights the critical need for early identification of patients at risk of malnutrition and the importance of timely intervention.

Sections du résumé

BACKGROUND BACKGROUND
Malnutrition and sarcopenia are challenges for patients with metastatic breast cancer and have been proposed as independent prognostic factors. Very few studies have addressed the temporal evolution of these parameters and, notably, the separate and combined analysis of sarcopenia and malnutrition. This study aimed to i) determine the prevalence of malnutrition and sarcopenia, individually and combined, and their evolution over time, ii) identify risk factors for each condition, and iii) explore their impact on overall survival (OS).
METHODS METHODS
This retrospective study was conducted on 111 patients treated for at least a third-line metastatic breast cancer at the Institut Curie between January 1st and March 31st, 2018. Solitary malnutrition was defined from weight loss and body mass index values while solitary sarcopenia was defined solely based on low muscle mass. We analyzed solitary malnutrition, solitary sarcopenia, and then malnutrition with or without sarcopenia, at three key stages (T1: diagnosis of metastasis, T2: initiation of third-line treatment, and T3: 3-month re-evaluation). Univariate and multivariate logistic regression analyses were conducted to investigate the risk factors. We performed Cox proportional hazards analyses for each variable.
RESULTS RESULTS
At T1, the prevalence of solitary malnutrition, solitary sarcopenia and malnutrition with or without sarcopenia was 18.6%, 36.1% and 48.9% respectively, increasing to 27.7%, 45.5% and 56.6% at T2. At T2, in multivariate logistic regression analyses, patients aged over 60 years were at an elevated risk of experiencing solitary malnutrition as well as malnutrition with or without sarcopenia, but not solitary sarcopenia. In multivariate analyses, solitary malnutrition was significantly associated with poorer OS (HR 2.2 [95% CI 1.1-4.1], p = 0.02), while solitary sarcopenia and malnutrition with or without sarcopenia showed no association.
CONCLUSION CONCLUSIONS
Solitary malnutrition and sarcopenia were highly prevalent in patients with metastatic breast cancer, affecting around a quarter and half of patients respectively at third-line treatment initiation. Notably, solitary malnutrition emerged as a prognostic factor for overall survival, whereas no significant association was observed for solitary sarcopenia or malnutrition with or without sarcopenia. This highlights the critical need for early identification of patients at risk of malnutrition and the importance of timely intervention.

Identifiants

pubmed: 38908032
pii: S0261-5614(24)00206-1
doi: 10.1016/j.clnu.2024.06.014
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1710-1718

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare no conflict of interest.

Auteurs

Géraldine M Camilleri (GM)

Department of Supportive Care, Institut Curie, 75005 Paris, France. Electronic address: geraldine.camilleri@curie.fr.

Lidia Delrieu (L)

Residual Tumour & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Institut Curie, Paris University, 75005 Paris, France; Institute for Biomedical and Epidemiological Research in Sport, EA7329, Paris, France University, Paris, France; INSEP, Institut National du Sport de l'Expertise et de la Performance, Paris, France.

Carole Bouleuc (C)

Department of Supportive Care, Institut Curie, 75005 Paris, France.

Jean-Yves Pierga (JY)

Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France; Circulating Tumor Biomarkers laboratory, Inserm CIC-BT 1428, Institut Curie, Paris France; Université Paris Cité, France.

Paul Cottu (P)

Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France.

Frédérique Berger (F)

Institut Curie, PSL Research University, DREH, Department of Biometrics, Saint-Cloud, France.

Bruno Raynard (B)

Department of Supportive Care, Unit of Nutrition, Gustave Roussy, 24 Rue Albert Thuret, 94550 Chevilly-Larue, France.

Stacy Cyrille (S)

Institut Curie, PSL Research University, DREH, Department of Biometrics, Saint-Cloud, France.

Timothée Marchal (T)

Department of Supportive Care, Institut Curie, 75005 Paris, France. Electronic address: timothee.marchal@curie.fr.

Classifications MeSH